Abstract
The invention concerns methods of treating suicidal ideation or behavior in a subject in need thereof, comprising decreasing endogenous nicotinic acetylcholine receptor (nAChR) activity in the subject; therapeutic packages for treating suicidal ideation or behavior; and methods for determining the efficacy of a treatment for suicidal ideation or behavior. In some embodiments, the treatment methods comprise administering to the subject an effective amount of an inhibitor of a nAChR, such as a lithium compound, mecamylamine, clozapine, or asenapine.
Claims
- A method of treating suicidality in a subject in need thereof, comprising administering to the subject an effective amount of mecamylamine or TC-5214.
- The method of claim 1, wherein the subject has suicidal thoughts and is at risk of committing suicide.
- The method of claim 1, wherein the subject has tried to commit suicide or has a history of suicide attempts.
- The method of claim 1, wherein the subject is further suffering from ambulatory bipolar disorder, schizophrenia, or both.
- The method of claim 1, wherein the subject is identified as suffering from suicidality using a suicidality tracking scale capable of direct mapping to the Columbia Classification Algorithm for Suicide Assessment (C-CASA).
- The method of claim 1, wherein the subject is identified as suffering from suicidality using the Sheehan Suicidality Tracking Scale (S-STS) or Columbia Suicide Severity Rating Scale (C-CRS).
- The method of claim 1, wherein the subject is identified as having suicidality symptoms of more than zero as measured by the Sheehan Suicidality Tracking Scale (S-STS) prior to said administering.
- The method of claim 1, wherein the subject has an abnormally low brain-derived neurotrophic factor (BDNF), or cerebrospinal fluid (CSF) monoamine metabolite, concentration prior to said administering.
- The method of claim 8, wherein the monoamine metabolite is 5-hydroxyinoleacetic acid (5-HIAA).
- The method of claim 1, wherein the subject has a polymorphism in the tryptophan hydroxylase gene in intron 7.
- The method of claim 1, wherein the subject has had a major depressive episode.
- The method of claim 1, wherein the subject is suffering from bipolar depression.
- The method of claim 1, wherein the subject is suffering from an anxiety disorder or anxiety symptoms.
- The method of claim 1, wherein the subject is further suffering from a disorder selected from the group consisting of bipolar disorder, panic disorder, social anxiety, post-traumatic stress disorder (PTSD), substance dependence/abuse, eating disorder, obsessive compulsive disorder (OCD), schizophrenia, schizo-affective disorder, schizophrenoform disorder, Huntington's disease, early Alzheimer's disease, and Parkinson's disease.
- The method of claim 1, wherein the mecamylamine or TC-5214 is administered as a monotherapy.
- The method of claim 1, wherein no mood stabilizing, antidepressant, antipsychotic, or anxiolytic medication, other than an nAChR inhibitor, is administered to the subject concurrently with the mecamylamine or TC-5214, or administered less than one week prior to administration of the mecamylamine or TC-5214.
- The method of claim 1, wherein the subject is administered a mood stabilizing, antidepressant, antipsychotic, or anxiolytic medication at least one week, prior to administration of the mecamylamine or TC-5214.
- The method of claim 1, wherein both mecamylamine and TC-5214 are administered to the subject.
- The method of claim 1, wherein the mecamylamine is administered to the subject.
- The method of claim 1, wherein the subject has not suffered a major depressive episode.
- The method of claim 1, wherein the subject is not suffering from major depressive disorder.
- The method of claim 1, wherein the subject is not suffering from bipolar disorder.
- The method of claim 1, wherein the suicidality is thereby eliminated.
- The method of claim 1, wherein the suicidality is non-drug-induced.
- The method of claim 1, wherein the TC-5214 is administered to the subject.
Owners (US)
-
University Of South Florida
(Apr 23 2012)
Explore more patents:
Applicants
-
Sheehan David Vincent
Explore more patents:
-
Shytle Roland Douglas
Explore more patents:
-
Univ South Florida
Explore more patents:
Inventors
CPC Classifications
-
A61K2300/00
Explore more patents:
-
A61K31/407
Explore more patents:
-
A61K31/55
Explore more patents:
-
A61K31/5513
Explore more patents:
-
A61K33/14
Explore more patents:
-
A61K45/06
Explore more patents:
IPC Classifications
-
A61K31/407
Explore more patents:
-
A61K31/55
Explore more patents:
-
A61K31/5513
Explore more patents:
-
A61K33/14
Explore more patents:
-
A61K45/06
Explore more patents:
-
A61K8/41
Explore more patents:
-
C07K14/705
Explore more patents:
Download PDF
Document Preview
Document History
- Publication: Nov 10, 2015
-
Application:
Oct 15, 2010
US 201013502239 A
-
Priority:
Oct 15, 2010
US 201013502239 A
-
Priority:
Oct 15, 2010
US 2010/0052949 W
-
Priority:
Oct 16, 2009
US 25234309 P